ERBB2 and breast carcinoma: In women under the age of 50, approximately 26.5% of breast cancer cases are hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) [2], whereas the incidence of this subtype is 70% when all age groups are considered [3].